Beyond Biopsy: The Menghini Needle As The Key Tissue Interface in The Era Of Precision Medicine For Pancreatic Diseases

Currently, the diagnostic and therapeutic paradigm for pancreatic diseases is undergoing a profound transformation, moving rapidly from "group-based" treatment based on morphology towards the era of "precision medicine" based on molecular characteristics. Within this grand vision, the role of ultrasound-guided fine needle aspiration (EUS-FNB) is being redefined: it is no longer merely the endpoint for obtaining a "diagnosis", but rather the starting point for initiating a series of advanced molecular analyses and guiding individualized treatment. In this value chain transition, the performance of the biopsy needle has been given unprecedentedly high standards. The Menghini needle, with its potential advantage in tissue quality brought about by the "inward inclined cutting and negative pressure extraction" design, is expected to surpass its traditional role as a diagnostic tool and evolve into an indispensable key "tissue interface" connecting clinical practice with cutting-edge life science research.
I. The Demand for Precision Medicine: Why "Organizational Quality" Has Become the New Currency?
For solid tumors such as pancreatic cancer, modern treatment decisions increasingly rely on a thorough analysis of the biological behavior of the tumors:
1. Molecular Typing and Targeted Therapy: Identifying gene mutations such as KRAS, TP53, SMAD4, as well as molecular characteristics like microsatellite instability and homologous recombination repair defects, is crucial for screening targeted drugs and immune checkpoint inhibitors.
2. Prognosis Assessment and Recurrence Monitoring: Specific gene expression profiles and mutation loads are closely related to the prognosis of patients.
3. Organoid Culture and Drug Sensitivity Testing: Culturing "mini-tumors" from fresh tumor tissues of patients in vitro for high-throughput drug screening is one of the ultimate visions for achieving "individualized" treatment.
All these advanced applications are based on a common foundation: obtaining high-quality tissue specimens that are of sufficient quantity, have high cellular activity, have intact DNA/RNA, and can represent the heterogeneity of the tumor. Tissues that are severely fragmented or compressed will have their nucleic acids degraded, cellular activity lost, and cannot be used for cultivation, nor can their molecular detection results be guaranteed to be representative.
II. Menghini Needle: A Tailored Tissue Acquisition Solution for Precision Medicine
Unlike the strategy that solely focuses on maximizing "the quantity of organization acquisition", Menghini's design concept precisely responds to the stringent "quality" requirements of precision medicine:
1. Preservation of cell viability and nucleic acid integrity: The "picking" method used here causes less mechanical shear stress and thermal damage to cells compared to "rotational cutting" or "hooking". This helps maintain a higher cell survival rate, providing the possibility for subsequent fresh tissue live cell sorting, primary cell culture, and even the construction of patient-derived xenograft models. Additionally, less physical damage means a lower risk of nucleic acid degradation, ensuring the accuracy and success rate of genetic sequencing.
2. Maintenance of tissue structure and spatial information: A relatively complete micro-tissue column not only contains tumor cells but also retains some tumor microenvironment information, such as stromal cells, immune cell infiltration, and vascular structure. This is crucial for conducting cutting-edge analyses such as spatial transcriptomics and multiple immunofluorescence, helping to understand the interaction between tumors and the microenvironment, and discovering new therapeutic targets and biomarkers.
3. Reduction of blood dilution and improvement of tumor cell purity: Efficient and rapid cutting acquisition may reduce the time that the needle path stays and moves within the lesion, thereby lowering the proportion of normal blood mixed into the specimen. Higher-purity tumor tissue can improve the signal-to-noise ratio of downstream molecular detection, making the detection of low-frequency mutations more reliable.
III. From "Obtaining Diagnosis" to "Empowering Research": The Expanded Role of Menghini Needles
Based on these characteristics, the application scenarios of Menghini needles can be significantly expanded:
* Construction of a prospective biological sample bank: In clinical research projects, the use of Menghini needles enables systematic and standardized collection of high-quality pancreatic tumor samples that can be used for multi-omics analysis, accumulating valuable resources for discovering driver genes, verifying new targets, and exploring drug resistance mechanisms.
* "Biopsy-organoid" integrated platform: While obtaining diagnostic tissues, a portion of fresh specimens that have not been fixed with formalin can be specially reserved and immediately sent to the laboratory for organoid cultivation. Successful organoids can not only be used for drug sensitivity testing, but also serve as excellent models for studying tumor biology.
* Guidance for neoadjuvant and adjuvant therapy: For locally advanced pancreatic cancer, the application of neoadjuvant therapy is increasingly widespread. Comparing molecular profiles before and after treatment can dynamically observe tumor evolution and the emergence of drug-resistant clones. High-quality paired samples obtained by the Menghini needle are ideal materials for such dynamic studies.
IV. Challenges and Co-evolution
Of course, to achieve this vision, both the Menghini needle technology itself and the entire system need to evolve collaboratively:
1. Standardized operation procedures: It is necessary to establish a standardized workflow from puncture, negative pressure control, specimen extraction, to rapid packaging and transportation (some specimens are placed in fixative, some in cryopreservation tubes or culture media), ensuring that the quality of specimens obtained from different centers and by different operators is comparable.
2. Multi-disciplinary team collaboration: This requires close cooperation among endoscopists, pathologists, molecular pathologists, bioinformaticians, and basic researchers to form a seamless assembly line from "bedside sampling" to "laboratory analysis".
3. Cost-benefit consideration: Advanced molecular testing and organoid cultivation are costly. Menghini needle needs to prove that the high-quality tissues it provides can increase the detection success rate and information value, which is sufficient to offset its slightly higher cost than traditional methods, or to demonstrate overall economic benefits by reducing repeated punctures and avoiding invalid detections.
Conclusion: The Bridge Leading to the Future
In the wave of precision in the diagnosis and treatment of pancreatic diseases, the value of the Menghini needle has been elevated. It is no longer just one of the many excellent biopsy needles available; instead, thanks to its inherent optimization of tissue quality, it has become a highly promising bridge connecting conventional clinical diagnosis with cutting-edge precision medicine. It represents a future-oriented biopsy concept: every puncture should not merely aim to obtain a "benign/malignant" conclusion, but should strive to open a door to the most individualized and advanced treatment for the patient. When an endoscopist uses the Menghini needle for puncture, he is not only seeking a diagnosis for today's patient, but also possibly preserving a crucial life code for tomorrow's medical breakthrough. This expansion of role has made the modern revival of this classic design of the Menghini needle full of the sense of mission and forward-looking significance of the times.